Syngene International Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 10,000,000 (45%) | — | ₹25,000 Cr |
| NII (HNI) | — | 3,000,000 (14%) | — | ₹7,500 Cr |
| Retail | — | 7,000,000 (32%) | — | ₹17,500 Cr |
| Σ Total | — | 22,000,000 (100%) | — | ₹550,000 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 60 | ₹15,000 |
| Retail (Max) | 13 | 780 | ₹195,000 |
| S-HNI (Min) | 14 | 840 | ₹210,000 |
| B-HNI (Min) | 67 | 4,020 | ₹1,005,000 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Dec 14 | 31 Mar 14 | 31 Mar 13 |
|---|---|---|---|
| Revenue | 618 | 708 | 554 |
| Profit After Tax | 119 | 135 | 102 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 To Meet Working Capital Requirement – 28.40
- 2 Public Issue Expenses – 4.00
Company Overview
Incorporated in 1993, Syngene International Ltd is a subsidiary of Biocon Limited ("Biocon"), a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds.
Headquartered in Bengaluru, Syngene International is India-based contract research organisations ("CRO"), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities ("NMEs") across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Their services in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates ("ADC") and oligonucleotides.
Syngene offer customized models as per their clients requirements. These range from a full-time equivalent ("FTE") to a fee-for-service ("FFS") model, or a combination thereof. Till Dec 31, 2014, they serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014. Company's long term clients includes global healthcare organisations Bristol-Myers Squibb Co. ("BMS"), Abbott Laboratories (Singapore) Pte. Ltd. ("Abbott") and Baxter International Inc. ("Baxter").